Loading clinical trials...
Loading clinical trials...
Expanded Access Program for SNDX-5613 in Patients With Relapsed/Refractory Acute Leukemias With Genetic Alterations Associated With HOXA Overexpression
Conditions
Interventions
Revumenib
Locations
35
United States
Alabama Center for Childhood Cancer And Blood Disorders, Children's of Alabama
Birmingham, Alabama, United States
Phoenix Children's Hospital
Phoenix, Arizona, United States
City of Hope
Duarte, California, United States
City of Hope at Orange County Lennar Foundation Cancer Center
Irvine, California, United States
UCLA, UCLA RRMC, Drug Information Center, Department of Pharmaceutical Services Drug Supply Shipment
Los Angeles, California, United States
Lucile Packard Children's Hospital-Stanford
Palo Alto, California, United States
Last Updated
September 5, 2025
Lead Sponsor
Syndax Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions